Navigation Links
Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
Date:9/30/2010

FREDERICK, Md., Sept. 30 /PRNewswire/ -- Vaccinogen, Inc. has appointed veteran biotechnology executive Michael L. Kranda as President and Chief Executive Officer to guide it through its next stage of growth.

"The timing couldn't be better – as the company proceeds to finance and launch our pivotal Phase III clinical trial," said Michael G. Hanna, Jr., Ph.D., Vaccinogen's Founder & Chairman and inventor of the company's unique cancer-fighting vaccine OncoVAX®.

Co-founder and COO Andrew L. Tussing said Mr. Kranda was the clear choice to head the break-through biopharmaceutical company.  "He has the vision and experience to lead us through this important phase in our growth," Mr. Tussing said.

"I'm excited about OncoVAX®'s potential to save lives and Vaccinogen's role as a pioneer in using autologous vaccines to combat cancer," said Mr. Kranda.  "I look forward to building on the OncoVAX® technology to create an important and leading company in the cancer vaccine arena."

Literally Turning Cancer on Itself™, Vaccinogen works to harness the body's immune system to prevent the recurrence of cancer in patients recovering from the disease.

Mr. Kranda brings to Vaccinogen more than two decades of experience developing biotechnology platforms, products and companies. He sits on the board of directors of several companies including PTC Therapeutics.

Previously, Mr. Kranda served as the CEO, President and Director of Anesiva. Prior to joining Anesiva, Mr. Kranda was Managing Director of Vulcan Capital, Paul Allen's investment arm, where he led the life science venture investments team.  Mr. Kranda also served as CEO of Oxford GlycoSciences, and led their listings on the LSE and NASDAQ exchanges and prior to that was President and COO of Immunex (now Amgen).

Mr. Kranda holds a BA and an MBA from the University of Washington School of Business.

About OncoVAX®OncoVAX® transforms the body's immune response to prevent the return of the disease after surgery. As published in the journal Human Vaccines, Stage II OncoVAX® patients achieve "a 57.1% relative risk reduction in the recurrence of colon cancer" vs. the control patients in a previous clinical trial.

About VaccinogenVaccinogen develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer in various stages of clinical development.

www.vaccinogeninc.comContact:Andrew L. TussingVaccinogenatussing@vaccinogeninc.com301-668-8400
'/>"/>

SOURCE Vaccinogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RF Technologies® Names Mark Harwood New President
2. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
3. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
4. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
5. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
8. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
11. Thomson Reuters Names the Worlds Hottest Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
Breaking Biology News(10 mins):